Only 10% of breast cancer is hereditary. Which means 90% is not. Now, you can't change your genes, but healthier lifestyle choices can make a difference.
Only 10% of breast cancer is hereditary. Which means 90% is not. Now, you can’t change your genes, but healthier lifestyle choices can make a difference.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Tucatinib/Letrozole/Palbociclib Combo Shows Initial Efficacy in HR+/HER2+ Metastatic Breast Cancer
August 19th 2023At median follow up of 33.6 months, patients who received the triplet combination of tucatinib, letrozole, and palbociclib, experienced a median progression-free survival of 8.4 months.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
2 Clarke Drive
Cranbury, NJ 08512